[go: up one dir, main page]

WO2025137661A1 - Combination treatment of neurological disorders - Google Patents

Combination treatment of neurological disorders Download PDF

Info

Publication number
WO2025137661A1
WO2025137661A1 PCT/US2024/061617 US2024061617W WO2025137661A1 WO 2025137661 A1 WO2025137661 A1 WO 2025137661A1 US 2024061617 W US2024061617 W US 2024061617W WO 2025137661 A1 WO2025137661 A1 WO 2025137661A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
neurological disorders
combination treatment
prodrug
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/061617
Other languages
French (fr)
Inventor
Steven I. DWORETZKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of WO2025137661A1 publication Critical patent/WO2025137661A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of treating a depressive disorder, or a neurological or neurodegenerative disorder in a subject includes administering to the subject a therapeutically effective amount of a Kv7 channel activator of Formula I, or a pharmaceutically acceptable salt thereof, in combination with a prodrug of an NMDA receptor antagonist of Formula II, or a pharmaceutically acceptable salt thereof: Formula I, Formula II. A pharmaceutical composition including the Kv7 channel activator and the prodrug of the NMDA receptor antagonist is also disclosed.

Description

-- - , ,.. ... , . ,,.. . , , , , , , , ,. .. ... , . . + .. . - , . , . . , , ., , .. , , , , . -- - , , , ,
Figure imgf000003_0001
, , ,- 4, - . . * . . .,,,,. –., ., . –. , . ., ,,, , . –.., . ., .,,,, ,. -- - ,,,. –. , , ., . . –.. . ,,, , ., ., . , –. , ,,. , ., , . –. , ., , , ., . -. . . , . ,,,, , .. . . . . ..,, .,, . . -- - , . ,, . . , “” “” “”, “” “. “ ”” . . “ - -- . , ” “ ” .., . , . , - “ ” ,,, . “ ” . , .., 1, , , . ,..,-. . , . -- - . , , , ,, , , ,. . , “ ”. , . . , , , , , , , , , , , , ,, , , , , , , , , , , , , , , , ,- , , -, . , , ,,.-.2n- ,., ,, ,. . . -, , ,. “ ” . “ , , ” ,.., ,. , , , , - .. “ ” “ ,” , , -- -“ ” ,. “ ” , ” “.” “ ” - . “- ,, , , - ,, ,. , “ ”, “ ” . ,. , , , , ", " “ . . ” , , , ,, . , . , ,, . . , . , . , . .., ..,, , -- - ., , . , , , . , . ,
Figure imgf000008_0001
, , -4 . - , , - , ,..,1,2,, 4 1 . 2, 1 1 –2 7,-7.. , 7 , ,., 22,--. . 2 . 4. . ,.4. -- -
Figure imgf000009_0001
,
Figure imgf000009_0002
, , . “ . .
Figure imgf000009_0003
-- - , - , , , , , ., , , , , , , , , , ., ,, , , , , , , , , , ,,, ,. , . ,, .
Figure imgf000010_0001
, . ”, . . . , , , , , , - ,, , , . , , ,. . ., . ., ,, , . - ..., , -- - . ,, . , ,. , ,, , , , , , ,- , , , , , , , , , , , , ,, , , , ’, ,' ,, , - , ,,, , , ,, , , , ,. , ' , ’ , , ,, , , , , . . , , ,, ,, , . , , , - , -- - . , . , , . . , , .. , . . ,, , , . , , , . . . , . , , , .. , ,. . ., . . -- - . , . , ,. , . , . ,,.., ,. ,, ,, , , ,, ,.., . . , . , , , , , , , , , , , , , , , . , . ,, , , , , . . - .
-- - . ,,, ,,, , , . ,. , , ,-,. . . ,.., , . , . , - . ,..,-, ..-... - ... . , . . , . ,.., . , , . . -- - - .., , . ' - . , - . - ~ . . - , , -, ., - ,. . - , , , , , . , . . . . ,~ , . - -. .,. - , , - . ,,, . , =,,,.,,,,,,,,, .. –. - . , . ., -- - . - . , , . = - . ., = , . . , ,.., . - - . - , . - ,..., .. ,*, , - . ,.., - , .. . - .. . =, =,, , , ,, . - .- , . . , .-, -- - , =... , – ., . . ,- ., . , , =, , , . , ..- , .- , ,.., ,. . . , , . , . , , .-. , , , -- - . , .-. -- - .. - .- ,- - , , ,, ..,- . . , . - . , - =,. =, , -,.,, , ... . . - .. , =, , = .-..,-, ,. , . , -. . . -- -, , , , , .

Claims

-- - . , , , ,
Figure imgf000020_0001
, , , ,- 4 - - . . , , , , , , ,, - , , ,, , . . , , , ,
-- - ,
Figure imgf000021_0001
, ,-4 - . . , , ,, , , , , ,- , ,, , , , , , , , , , , , , , ,, , , ’, ' , , , - , , , , , , , , , , , , , ' , , . ’ , . , . . , .
Figure imgf000021_0002
-- - . , . . , . . ,
Figure imgf000022_0001
. , .
Figure imgf000022_0002
-- - . , .
Figure imgf000023_0001
. ,
Figure imgf000023_0002
,
Figure imgf000023_0003
. . , . . , , . -- - . , , , , ,
Figure imgf000024_0001
,4 - , ,-4 -, . . , , ,
Figure imgf000024_0002
-- -
Figure imgf000025_0001
. ,
Figure imgf000025_0002
. . ,
Figure imgf000025_0003
. . ,
Figure imgf000025_0004
-- - .
Figure imgf000026_0001
, .
PCT/US2024/061617 2023-12-22 2024-12-22 Combination treatment of neurological disorders Pending WO2025137661A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363614497P 2023-12-22 2023-12-22
US63/614,497 2023-12-22
US202463617796P 2024-01-05 2024-01-05
US63/617,796 2024-01-05
US202463652374P 2024-05-28 2024-05-28
US63/652,374 2024-05-28

Publications (1)

Publication Number Publication Date
WO2025137661A1 true WO2025137661A1 (en) 2025-06-26

Family

ID=96138845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/061617 Pending WO2025137661A1 (en) 2023-12-22 2024-12-22 Combination treatment of neurological disorders

Country Status (1)

Country Link
WO (1) WO2025137661A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190152914A1 (en) * 2013-11-05 2019-05-23 Astrazeneca Ab Nmda antagonist prodrugs
WO2019183148A1 (en) * 2018-03-19 2019-09-26 Knopp Biosciences Llc Kv7 channel activators compositions and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190152914A1 (en) * 2013-11-05 2019-05-23 Astrazeneca Ab Nmda antagonist prodrugs
WO2019183148A1 (en) * 2018-03-19 2019-09-26 Knopp Biosciences Llc Kv7 channel activators compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FENG ET AL.: "Reversal of a treatment-resistant, depression-related brain state with the Kv7 channel opener retigabine", NEUROSCIENCE, vol. 406, 15 May 2019 (2019-05-15), pages 109 - 125, XP085682684, DOI: 10.1016/j.neuroscience.2019.03.003 *

Similar Documents

Publication Publication Date Title
JP2609968B2 (en) Treatment of emotional disorders with glycine / NMDA receptor complex functional antagonists
JP2010535801A5 (en)
MXPA04011547A (en) Novel methods and compositions for alleviating pain.
JPH03148221A (en) D-cycloserine and d-alanine containing composition for treating the disorder of memory and learning for treating the disorder of memory and learning rate or the disorder of recognition or mind
NZ583192A (en) Methods for treating dependence
ZA200301865B (en) New treatments for restless legs syndrome.
KR20230141875A (en) Ketamine as an N-methyl d-aspartate receptor (NMDAR) antagonist
RU2010107843A (en) BUPROPION HYDROBROMIDE AND ITS THERAPEUTIC APPLICATIONS
MX2023007058A (en) Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders.
KR100341952B1 (en) Primary and Secondary Neuroprotective Effects of Flopirtine in Neurodegenerative Diseases
DE60317935T2 (en) ALPHA AMINOAMIDE DERIVATIVES AS AGENTS AGAINST MIGRAINE
WO2025137661A1 (en) Combination treatment of neurological disorders
de Jong Ropivacaine: White knight or dark horse?
JP2008512405A5 (en)
JP3120810B2 (en) Method for producing a compound for treating a neurodegenerative disease
MX2025008555A (en) 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
US7384959B2 (en) Treatment of convulsive states
WO2004014391B1 (en) Use of carboxamides for the treatment of tinnitus
Ueta et al. In vitro antagonism of recombinant ligand-gated ion-channel receptors by stereospecific enantiomers of bupivacaine
WO2023158955A3 (en) 3α-OH-5β-PREGNAN-20-ONE COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS
Liebetanz et al. Pharmacology of transcranial direct current stimulation: missing effect of riluzole
US7851485B2 (en) Therapeutic agent for neuropathic pain
Bo et al. EEG and behavioural effects of polyamines (spermine and spermidine) on rabbits
JP2014240417A (en) Method of treatment of depression
Foong et al. Analgesic potencies of non-narcotic, narcotic and anesthetic drugs as determined by the bradykinin-induced biting-like responses in rats

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24909146

Country of ref document: EP

Kind code of ref document: A1